Current treatment concepts of CML

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Chronic myeloid leukemia (CML) is driven by a specific molecular mechanism.
• Imatinib, a tyrosine kinase inhibitor, revolutionized CML treatment, becoming the standard therapy.
• A notable subset of CML patients exhibit intolerance or resistance to imatinib.

Purpose of the Study:

• To review current knowledge on the diagnosis, monitoring, and therapeutic strategies for CML.
• To highlight the challenges in managing imatinib failure and disease progression.
• To emphasize the role of second-generation tyrosine kinase inhibitors and mutational analysis.

Main Methods:

• Literature review of diagnosis, monitoring, and therapy strategies for CML.
• Analysis of imatinib efficacy and limitations in CML treatment.
• Discussion of alternative targeted therapies and prognostic indicators.

Main Results:

• Imatinib offers impressive response and survival rates but is not universally effective.
• Early recognition of imatinib failure is crucial to prevent disease progression.
• Second-generation tyrosine kinase inhibitors, guided by mutational analysis, offer alternative treatment options.

Conclusions:

• Effective management of CML requires vigilant surveillance for imatinib failure.
• Personalized therapeutic approaches, including mutational analysis, are essential for optimizing CML patient outcomes.
• Understanding current and emerging treatment strategies is vital for clinicians managing CML.